Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine versus sufentanil for prevention of intraoperative hypoxia during sedated hysteroscopic surgery
ChiCTR2400090351Phase 4Recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of oliceridine, sufentanil and propofol in pain (2 arms), sponsored by Renji Hospital. Primary endpoint: Incidence of hypoxia during sedated hysteroscopy. Started Sep 2024; status: recruiting.
02
Drugs
oliceridinesufentanilpropofol
03
Conditions
pain
Beyond the preview
Go deeper on ChiCTR2400090351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090351.